Brian Savage - 05 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Interim Chief Legal Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage
Issuer symbol: TEVA
Transactions as of: 05 Mar 2026
Net transactions value: -$35,690
Form type: 4
Filing time: 09 Mar 2026, 16:09:13 UTC
Previous filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Savage Brian	Interim Chief Legal Officer	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A STREET, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage	09 Mar 2026	0002112339

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+3,580	+42%		12,041	05 Mar 2026	Direct	F1, F2
transaction	TEVA	Ordinary Shares	Sale	$35,690	-1,127	-9.4%	$31.67	10,914	05 Mar 2026	Direct	F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise		-3,580	-25%	$0.000000^*	10,740	05 Mar 2026	Ordinary Shares	3,580		Direct	F1, F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5	Restricted share units were granted on March 5, 2025, with 3,580 vested on March 5, 2026, and 3,580 vesting on each of March 5, 2027, March 7, 2028 and March 5, 2029.